PMID- 16156422
OWN - NLM
STAT- MEDLINE
DCOM- 20051108
LR  - 20191109
IS  - 1098-3597 (Print)
IS  - 1873-4480 (Linking)
VI  - 7
IP  - 1
DP  - 2005
TI  - Available and future treatments for erectile dysfunction.
PG  - 37-45
AB  - There is now a range of treatments for patients with erectile dysfunction (ED) 
      beyond the psychosexual counselling and surgical implants that were the only 
      available management options for many years. Oral treatments, which are minimally 
      invasive, are the favoured first-line option for treatments and include the 
      phosphodiesterase-5 (PDE5) inhibitors, and dopamine agonists such as apomorphine. 
      Psychosexual counselling may still be an appropriate treatment, on its own or in 
      combination, in a minority of patients who do not respond to oral treatment, or 
      where an origin for the ED is likely from the history. The PDE5 inhibitors, 
      sildenafil, tadalafil, and vardenafil, have proven to be effective and well 
      tolerated and facilitate erectile function. Apomorphine is also effective, but 
      causes nausea in a minority of men. The alpha-receptor antagonist yohimbine has 
      been found to be effective in some placebo-controlled trials, but its 
      effectiveness is probably inadequate for treatment of most ED. Intracavernosal 
      injection of drugs such as prostaglandin E1, papaverine, and phentolamine 
      (sometimes in combination) is an effective but invasive treatment. Other 
      treatments include testosterone, vacuum-pump treatment, surgery, and surgical 
      implants, and tend to be used where patients do not respond to oral treatment and 
      counselling.
FAU - Dinsmore, Wallace W
AU  - Dinsmore WW
AD  - Royal Victoria Hospital, Belfast, UK.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Cornerstone
JT  - Clinical cornerstone
JID - 9816002
RN  - 0 (Phosphodiesterase Inhibitors)
RN  - 2Y49VWD90Q (Yohimbine)
RN  - 3XMK78S47O (Testosterone)
RN  - N21FAR7B4S (Apomorphine)
RN  - Z468598HBV (Phentolamine)
SB  - IM
MH  - Apomorphine/therapeutic use
MH  - Erectile Dysfunction/*drug therapy/physiopathology/surgery
MH  - Humans
MH  - Male
MH  - Phentolamine
MH  - Phosphodiesterase Inhibitors/therapeutic use
MH  - Testosterone/therapeutic use
MH  - Yohimbine/therapeutic use
RF  - 23
EDAT- 2005/09/15 09:00
MHDA- 2005/11/09 09:00
CRDT- 2005/09/15 09:00
PHST- 2005/09/15 09:00 [pubmed]
PHST- 2005/11/09 09:00 [medline]
PHST- 2005/09/15 09:00 [entrez]
AID - S1098-3597(05)80047-X [pii]
AID - 10.1016/s1098-3597(05)80047-x [doi]
PST - ppublish
SO  - Clin Cornerstone. 2005;7(1):37-45. doi: 10.1016/s1098-3597(05)80047-x.